Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × tucatinib × Gastrointestinal × Clear all

Phase

Phase 2 7 Phase 1 2 Phase EARLY_PHASE1 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 Breast 1

Conditions

Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 46 Fluorouracil 43 Capecitabine 36 Cisplatin 30 Leucovorin 26 Gemcitabine 22 Drug Therapy 18 Bevacizumab 17 Folfox protocol 15 Paclitaxel 14 Irinotecan 13 Radiotherapy 12 apatinib 10 Neoadjuvant Therapy 10 Docetaxel 9 sintilimab 8 Sorafenib 8 Nivolumab 8 Trastuzumab 7 Surgical Procedures, Operative 7 S 1 (combination) 7 lenvatinib 6 XELOX 6 Magnetic Resonance Spectroscopy 6 Cetuximab 6 nimotuzumab 5 camrelizumab 5 Ramucirumab 5 Radiosurgery 5 IFL protocol 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04499924 2025-01-22

MOUNTAINEER-02

Seagen Inc.

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon ⚡